Seminar Topic:
Translating Molecular Virology into Novel Antiviral Therapies

Professor Jeffrey Glenn
Professor of Medicine and Microbiology & Immunology
Division of Gastroenterology and Hepatology
Director, Center for Hepatitis and Liver Tissue Engineering
Stanford University School of Medicine, USA

Abstract
Dr Glenn will discuss some of his pioneering new approaches to antiviral therapy, including the concepts of targeting host functions upon which viruses depend and highly conserved viral RNA secondary structures. These have resulted in a pipeline of exciting novel therapeutics designed to target the worst form of human viral hepatitis, provide a cure for the common cold and paralyzing enterovirus infections of children, and yield a universal treatment for influenza virus including the most devastating pandemic strains.

Biography
Dr Jeffrey Glenn is a Professor of Medicine (Division of Gastroenterology & Hepatology) and Microbiology & Immunology at Stanford University School of Medicine, and the Director of the Center for Hepatitis and Liver Tissue Engineering. He also heads a research laboratory focused on studying molecular virology and the translation of that knowledge into novel antiviral strategies, as well as the development of new treatments for liver diseases and cancer. He is the founder of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), co-founder of Riboscience LLC, and founder of I-Cubed Therapeutics, local biotechnology companies developing several new classes of antiviral and anti-cancer drugs. Glenn was born in Los Angeles, and grew up in Switzerland. He received his B.A. degree in Biochemistry and French Civilization from U.C. Berkeley from where he graduated summa cum laude. He received his M.D. and Ph.D. in Biochemistry and Biophysics from U.C.S.F.. He trained in internal medicine at Stanford University where he completed specialty training in gastroenterology, and joined the faculty in 2000. He is the principal investigator on multiple NIH grants including a National Institute of Allergy and Infectious Diseases Center of Excellence for Translational Research, an inventor on numerous patents, an elected member of the American Society for Clinical Investigation, and a member of the FDA Antiviral Drugs Advisory Committee.

Wednesday, 28 November 2018 ǁ Time: 2:00 pm – 3:00 pm ǁ
Venue: MSE Meeting Room (N4.1-01-28)
Hosted by: Associate Professor Cho Nam-Joon